← Back to Clinical Trials
Recruiting NCT06286163

NCT06286163 Neuroinflammatory Interactions of ATP and P2X3 Receptor in the Airways of Chronic Cough Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06286163
Status Recruiting
Phase
Sponsor Imperial College London
Condition Chronic Cough
Study Type OBSERVATIONAL
Enrollment 18 participants
Start Date 2023-10-01
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 30 Years
Max Age 70 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 18 participants in total. It began in 2023-10-01 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is being done in order to understand what causes people to have a chronic cough, which is defined as a cough lasting for more than 8 weeks. The research team wish to find out whether there is any inflammation in the lungs of patients with chronic cough. The research team will also determine whether a suspected chemical produced in the body, called adenosine triphosphate (ATP) can be responsible for causing the chronic cough. In order to be able to find out what is abnormal in those who have a chronic cough, The research team will need to compare their results with those that do not have a chronic cough. In this study, the research team will examine 10 participants who suffer from chronic cough and 8 individuals who do not have a chronic cough and are healthy.

Eligibility Criteria

Inclusion Criteria: \- 1. For Normal non-smoking subject: Healthy individuals, free of significant disease No history of asthma/rhinitis, No therapies, Baseline FEV1 ≥80% predicted with FEV1/FVC ratio \>70% Non-smoker for at least the past 12 months with a pack history of ≤5 pack-years 2\. For chronic cough participants: History of chronic cough of at least 8 weeks' duration and should have been followed in the Cough Clinic for at least 6 months. Undergone a protocol with a diagnostic pathway as recommended by the ERS guidelines for management of cough. Would have either an identifiable cause for their cough that have failed therapies targeted towards the identified cause or classed as having chronic idiopathic cough where no identifiable cause has been found. 3\. General Inclusion Criteria: Give written informed consent prior to participation in the study including all of its procedures. Comply with the requirements and restrictions listed in the consent form. Male or female subject aged between 30 and 70 years old at screening. Able to complete the study and all measurements. Able to read, comprehend, and write at a sufficient level to complete study related materials. Exclusion Criteria: \-

Contact & Investigator

Central Contact

Kian Fan Chung, MD

✉ f.chung@imperial.ac.uk

📞 442075947959

Principal Investigator

Kian Fan Chung, MD

PRINCIPAL INVESTIGATOR

Imperial College London

Frequently Asked Questions

Who can join the NCT06286163 clinical trial?

This trial is open to participants of all sexes, aged 30 Years or older, up to 70 Years, studying Chronic Cough. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06286163 currently recruiting?

Yes, NCT06286163 is actively recruiting participants. Contact the research team at f.chung@imperial.ac.uk for enrollment information.

Where is the NCT06286163 trial being conducted?

This trial is being conducted at London, United Kingdom, London, United Kingdom.

Who is sponsoring the NCT06286163 clinical trial?

NCT06286163 is sponsored by Imperial College London. The principal investigator is Kian Fan Chung, MD at Imperial College London. The trial plans to enroll 18 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology